Cite
Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL).
MLA
Myers, Regina M., et al. “Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL).” Biology of Blood & Marrow Transplantation, vol. 26, Mar. 2020, p. S39. EBSCOhost, https://doi.org/10.1016/j.bbmt.2019.12.105.
APA
Myers, R. M., Kadauke, S., Li, Y., Callahan, C. A., Gladney, W., Fitzgerald, J. C., Wray, L., Leahy, A. B., Baniewicz, D., Motley, L. S., McGuire, R., Shenoy, V., Barrett, D. M., Teachey, D. T., Maude, S. L., DiNofia, A., & Grupp, S. A. (2020). Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL). Biology of Blood & Marrow Transplantation, 26, S39. https://doi.org/10.1016/j.bbmt.2019.12.105
Chicago
Myers, Regina M., Stephan Kadauke, Yimei Li, Colleen A. Callahan, Whitney Gladney, Julie C. Fitzgerald, Lisa Wray, et al. 2020. “Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL).” Biology of Blood & Marrow Transplantation 26 (March): S39. doi:10.1016/j.bbmt.2019.12.105.